No please Bpharma, educate us! How will we ever understand these...

No please Bpharma, educate us! How will we ever understand these announcements without you.

Tell us again how the company wasn't aiming to reach 50mg/kg and that the low doses were going to be effective.

And tell us how the higher cohorts were simply to elicit toxicity (the ethics committee would have loved that one).

James isn't being 100% upfront. The faster infusion would definitely be more practical. But it's likely that another reason why they are effectively starting a phase 1 again with faster infusion is to try and hit a higher peak plasma concentration.

Then, if successful, they will look to prove safety of repeat doses. If both higher (much higher) peak plasma concentrations and safe repeat dosing is achieved, then 327 may then be an incredible bacteraemia/sepsis drug for most/all pathogens of interest. If not they might go right back to the drawing board and try to modify 327 to prolong plasma half-life.

But for now, expect dialogue to reference UTI and urosepsis more and more, because that is where 327 currently shines.